AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05707741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmetomedine infusion
Description: 50 ml mixture of saline 48 ml and dexmedetomidine 200 μg
Study NCT05707741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmetomedine infusion
Description: 50 ml mixture of saline 48 ml and dexmedetomidine 200 μg
Study NCT06558253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme I for Injection
Description: Subjects received 21 consecutive days of intravenous infusion of Coenzyme I for injection, starting from the day of transplantation , and then continuously applied intravenously until 20 days post transplantation, with three dose groups: subjects #1-3 received one intravenous infusion per day containing 10 mg of Coenzyme I for injection, subjects #4-6 received one intravenous infusion per day containing 20 mg of Coenzyme I for injection, and subjects #7-12 received one intravenous infusion per day containing 50 mg of Coenzyme I for injection. Subjects in either dose group experienced a treatment-related Grade 3 or higher adverse reaction, the previous dose group was the maximum tolerated dose.
Study NCT06278168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Awareness training with using Oculus.
Description: The protocol consists of 2 phases:one conducted in groups,one individually. In the first session, through interactive activities such as passing a wool ball while sharing passions and interests, and filling out personal cards, participants get to know each other and develop an atmosphere of mutual acceptance.~In the second session,participants explore neurodiversity through viewing videos, guided discussions and creating symbols representative of the group concept. Optical illusions are explored to understand differences in individual perception.In addition, issues of hypersensitivity and hyposensitivity are addressed,encouraging participants to reflect on their special interests and ways of presenting themselves. The second phase consists of 12 individual meetings to promote emotional well-being and self-awareness. During the meetings, the Oculus device will be used in which relaxation videos will be shown. In addition, heart rate will be detected with sensors placed in the chest.
Study NCT06278168 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Awareness training without using Oculus
Description: The control group will carry out the same steps as the experimental group, heart rate will be taken through the use of sensors but in this case the Oculus device will not be used to watch relaxation videos.
Study NCT06159036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inertial Strength training
Description: Low speed strength training with classic movements, derived from Olympic lifting and jumping
Study NCT06159036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inertial Strength training
Description: Low speed strength training with classic movements, derived from Olympic lifting and jumping
Study NCT06056830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SAR-bisPSMA
Description: All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
Study NCT04877054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Treatment Program
Description: 4 telehealth sessions including a combination of psycho/medical education plus a motivational interviewing component.
Study NCT05039554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: Intervention will be provided over 12 weeks with weekly 1-hour sessions using a group format with the overall goal to foster psychological flexibility. ACT will assist participants to notice their internal triggers; abandon their attempts to manage these triggers via active avoidance (suppression or other control-based strategies including opioid or other substance use) and to make commitments to engage in behaviors consistent with their chosen values or goals (rather than allowing negative thoughts, feelings, or pain symptoms to dictate behavior).
Study NCT05039554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Valera Smartphone Application
Description: For those randomized to a cohort with the Valera app, the app (and cellphones if necessary) will be provided. The app is HIPAA compliant and IRB approved. It consists of 2 components: a participant-facing Smartphone Application and a corresponding online Care Manager Dashboard. Smartphones and internet access will be provided as needed for the 12-week study duration.
Study NCT05039554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Valera Smartphone Application
Description: For those randomized to a cohort with the Valera app, the app (and cellphones if necessary) will be provided. The app is HIPAA compliant and IRB approved. It consists of 2 components: a participant-facing Smartphone Application and a corresponding online Care Manager Dashboard. Smartphones and internet access will be provided as needed for the 12-week study duration.
Study NCT05039554 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: TAU for BUP treatment typically consists of regularly scheduled visits every 1-2 months with primary care physicians and/or nurse care managers in Montefiore primary care settings. During these 15-min follow up visits, providers typically inquire about opioid and other substance use, opioid craving, symptoms of opioid withdrawal, and risk of relapse. In addition, at each visit, urine toxicology tests are conducted and providers review results of prior urine toxicology tests with patients. If opioid or other substance use is ongoing, typically providers will intensify treatment, including increasing the frequency of visits, referring to social workers or mental health providers, recommending self-help groups, and/or recommending outpatient drug treatment programs (e.g., individual and group counseling).
Study NCT04877054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education only
Description: The control group will receive an education-only session. Education will include medication purpose and adherence strategy recommendations delivered in a single telehealth session.
Study NCT06435507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM-250 (50 mg)
Description: Single dose
Study NCT06435507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM-250 (100 mg)
Description: Single dose
Study NCT06435507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM-250 (200 mg)
Description: Single dose
Study NCT06435507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM-250 (400 mg)
Description: Single dose
Study NCT05666154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Real diet
Description: Diet excluding either trigger nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger)
Study NCT05666154 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham diet
Description: Diet excluding either sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
Study NCT05666154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wheat exclusion diet
Description: Diet excluding wheat in a blinded crossover fashion (CLE negative individuals without identified trigger)
Study NCT05666154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soy exclusion diet
Description: Diet excluding soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
Study NCT06235996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Office-based procedure indicated for chronic pain with music
Description: Such procedure may include sacroiliac joint (SI) steroidal injections, SI radiofrequency ablations, peripheral nerve stimulator implantations, caudal and laminar epidural steroidal injections, lumbar medial branch blocks, lumbar medial branch nerve radiofrequency ablations, spinal cord implantation of electro stimulators.
Study NCT06235996 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Office-based procedure indicated for chronic pain without music
Description: Office-based procedure indicated for chronic pain without music
Study NCT06518629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation with low power laser
Description: All groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whitness HP, FGM, Joinville, SC, Brazil). Three whitening sessions will be carried out, considering a seven-day interval between sessions.
Study NCT06518629 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation with low power laser
Description: All groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whitness HP, FGM, Joinville, SC, Brazil). Three whitening sessions will be carried out, considering a seven-day interval between sessions.
Study NCT06387056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezvilutamide
Description: 240mg by mouth once a day for 24 weeks.
Study NCT06387056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Microspheres for Injection
Description: 3.6mg by intramuscular injection once 4 weeks for 24 weeks.
Study NCT06387056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
Study NCT06387056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: 60mg by mouth twice a day for 20 weeks.
Study NCT06387056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
Study NCT06387056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
Study NCT05738863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Frequency rTMS Protocol
Description: It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex 5 days a week for 3 weeks, for a total of 15 sessions.~rTMS application Magventure MagPro R30 device is planned to provide magnetic stimulation with its stimulator. The stimulation pattern was shaped according to the protocols used in previous studies.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions.
Study NCT05738863 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS Protocol
Description: It was planned to apply the recorded beat sound to the primary motor cortex area daily 5 days a week for 3 weeks, for a total of 15 sessions by turning the TMS coil with the reverse side and in a 90-angle upright position.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions.
Study NCT06214728 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid gel application
Description: HA gel was applied to the periodontal pockets where the intraosseous defect was located using a sterile injector with a plastic needle. The gel was applied until it overflowed from the gingival sulcus. Patients were instructed not to eat, drink or brush their teeth for at least one hour. Subgingival application of HA was repeated 4 weeks after the first session.
Study NCT06214728 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel application
Description: The control group received placebo HA gel probe without rinsing. Placebo application was repeated 4 weeks after the first session.
Study NCT05581043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3-hydroxybutyrate (3-OHB)
Description: The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).
Study NCT05581043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate (3-OHB)
Description: The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).
Study NCT04725656 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Smoking cessation counseling at baseline, week 1, and week 4.
Study NCT04725656 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Smoking cessation counseling
Description: Smoking cessation counseling at baseline, week 1, and week 4.
Study NCT04725656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open system vape device and nicotine salt e-liquids
Description: Ad libitum use of nicotine salt e-liquids during three months.
Study NCT05178537 — intervention group
Intervention type: OTHER
Intervention: AAS users
Description: no intervention
Study NCT04847271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity on prescription (PAP)
Description: The intervention in this study will comprise the 3 PAP components. Participants will take part in all components and perform one or several physical activities of their choice in accordance to the written prescription, at the prescribed frequency and duration, for a period of 4 months.
Study NCT06233292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG005 Powder for Injection
Description: The dose groups of ZG005 for dose escalations are set as 0.3 mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, and 20mg/kg, intravenous infusion, once every 3 weeks.
Study NCT06233292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG005 Powder for Injection
Description: Recommended Phase 2 Dose (RP2D) of ZG005 monotherapy, intravenous infusion, once every 3 weeks.
Study NCT05796661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effects of increased blood flow during regional anticoagulation with 4% trisodium citrate in patients undergoing continuous venovenous hemodiafiltration
Description: Patients will be exposed to continuous venovenous renal therapy with distinct blood flows in 2 periods, to be defined by draw. The control group will have a flow of 150ml/min and the intervention group 250ml/min. Therapy is intended for a period of 72 hours (maximum defined by the manufacturer); with a 6-hour washout and, after that, the arm is changed to be exposed to the other blood flow.
Study NCT05796661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects of increased blood flow during regional anticoagulation with 4% trisodium citrate in patients undergoing continuous venovenous hemodiafiltration
Description: Patients will be exposed to continuous venovenous renal therapy with distinct blood flows in 2 periods, to be defined by draw. The control group will have a flow of 150ml/min and the intervention group 250ml/min. Therapy is intended for a period of 72 hours (maximum defined by the manufacturer); with a 6-hour washout and, after that, the arm is changed to be exposed to the other blood flow.
Study NCT05050214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Each patient will be treated for 1 month and received a total of 3 doses. The first dose of Obinutuzumab (1000 mg) will be split in two separate infusions; on the first day each patient will receive 100 mg and the next day 900 mg of Obinutuzumab. Obinutuzumab (1000 mg) will be also administered at two and four weeks after the first infusion. Obinutuzumab will be administered after standard premedication.
Study NCT06206980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion
Description: This intervention includes a hospital-based and a home-based intervention. During the hospital stay, the patients were provided with a health education which included information about pneumonia pathophysiology, healthy-lifestyle habits, benefits of being physically active, and any questions patients may have would be answered.~Additionally, an exercise program is provided, which includes resistance and aerobic exercise.~At the end of the hospital stay, a diary is provided to patients for recording the physical activity that performing the following 3 months. This diary is accompanied by phone calls at 15 days, 1 and 2 months of the hospital stay. During the phone calls, patients are motivated to increase their activity levels, and any questions patients may have, are answered.
Study NCT06206980 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional
Study NCT04702100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrument assisted soft tissue mobilization
Description: the patients will receive instrument-assisted soft tissue mobilization:The subject was seated in a relaxed sitting position. M2T blade was used to find specific areas of restriction on RT upper trapezius. Then treatment plane 1 - 2 and 3 were used.The lubricant (Vaseline) was applied to the skin around the neck area prior to treatment and the tool was cleaned with an alcohol preparation pad. Then by using M2T blade with angle 45, we were giving long slow strokes without causing any discomfort or pain over muscle starting from its insertion up to its origin approximately for 2 to 3 min repeated two times.
Study NCT04702100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated neuromuscular inhibition technique
Description: will receive integrated neuromuscular inhibition technique: from supine lying position.we the patients will perform ischemic compression at trigger points then positional release technique and finally muscle energy technique.
Study NCT04702100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: the patients will receive hot back for 10 minutes, active range of motion exercise, chin tuck, stretches
Study NCT04702100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: the patients will receive hot back for 10 minutes, active range of motion exercise, chin tuck, stretches
Study NCT05584826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: On 2 separate treatment visits, participants will receive dosing of 100 mg MDMA HCl (\~84 mg MDMA) + 40 mg MDMA HCl (\~34 mg MDMA) supplement unless tolerability issues arise from the first dose or the participant declines
Study NCT05918510 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx
Description: The prospective observational study involves the collection of tissue, blood and saliva samples from OPSCC and occult T patients for detection of HPV-DNA/RNA, miRNA and mutation profile from DNA with centralized analysis of samples at IRCCS Regina Elena National Cancer Institute.
Study NCT04967690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-053
Description: SI-053 will be used as an add-on to SoC for newly diagnosed GBM.In conjunction with surgical resection, SI-053 will be applied intracranially (i.c.) into the cavity that is formed after tumor resection. Post-operative chemoradiotherapy (including concomitant and adjuvant TMZ or following the CeTeG protocol) will be initiated at least 21 and no later than 35 days after SI-053 administration.
Study NCT04752280 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton irradiation
Description: proton irradiation applied as follows: 30 x 2 Gy(RBE) 33 x 1,8 Gy (RBE), or 15 x 2,67 Gy (RBE)
Study NCT04752280 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon irradiation
Description: proton irradiation applied as follows: 30 x 2 Gy 33 x 1,8 Gy, or 15 x 2,67 Gy
Study NCT05681403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Improved BEAM regimen
Description: Mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine will be used as conditioning regimen for ASCT in the lymphoma patients.
Study NCT04827290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-AGE diet
Description: Low-AGE diet during 24 months
Study NCT04827290 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-AGE diet
Description: High-AGE diet during 24 months
Study NCT05515029 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor
Description: Cyclophosphamide 100 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +45, +60, +90, +120 Vedolizumab 10 mg/kg/day, max. 300 mg on the days -1, +14, +28
Study NCT05165875 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone-Lidocaine
Description: Intervention will be done on the same day based on the randomization.~For the steroid injection group, a 1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants.